About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT00668655

An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1%

The purpose of this study is to determine the cosmetic appearance of metronidazole gel (MetroGel®) 1% with commonly marketed facial foundations.

Lead sponsor: Galderma R&D•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Galderma R&D

Evaluate the relationship between treatment with MetroGel® 1% and cosmetic performance with the Subjects' usual cosmetic products. It is expected that the female subjects will be able to use their routine cosmetics after application without affecting the cosmetic product's performance or causing side effects.

Age

20 - 75 years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•Subjects with moderate Rosacea (Global Severity Score of 3),
•Subjects willing to stop their current rosacea medication for at least 2 weeks
•Subjects must have an established routine of cosmetics application (e.g. must have been using the same facial foundation for at least 3 months and it is not expected to change during the study)
•Subjects must be willing to use their routine facial foundation and not change products while on study

Exclusion Criteria

•Subjects who do not routinely wear facial foundation
•Subjects who failed to undergo a washout period of 14 days for the use of topical rosacea therapy, (for example: metronidazole, azelaic acid, sulfacetamide)
•Subjects who are unwilling to stop their current rosacea medications for 2 weeks

Related studies

Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin

NCT07106957 · Erythematous Telangiectatic Rosacea

Research Into Diagnostic and Prognostic Molecular and Imaging Biomarkers of Ocular Disorders Associated With Neurovascular Deregulation: Biocor Cohort

NCT06466018 · Ocular Rosacea, Pachychoroid Disease

Active Not RecruitingEARLY Phase 1

Analysis of the Microbiome in Rosacea

NCT04108897 · Rosacea

Combined Therapy of 532-nm KTP and Microsecond 1064-nm Nd:YAG Laser for Rosacea

NCT07250165 · Rosacea

A Pilot Study to Explore the Role of Gut Flora in Acne

NCT04214483 · Acne, Acne Vulgaris, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 29, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment30

Start dateFeb 2008

Last updatedJul 29, 2022

Condition

Locations shown

Dermatology Consulting Services

High Point, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions